Gov. Hogan, Novavax’ Erck, & BIO’s Dr. McMurry-Heath Toured Novavax Labs and Discussed Progress on COVID-19 Vaccine
September 24 2020 - 4:35PM
Today, Maryland Governor Larry Hogan and Dr. Michelle
McMurry-Heath, President & CEO of Biotechnology Innovation
Organization (BIO), joined Novavax President & CEO Stanley Erck
to discuss the importance of the biotechnology sector in Maryland,
the industry’s efforts to address COVID-19, and progress being made
by Novavax to develop a vaccine for the deadly virus. A video of
the remarks is now available.
A video accompanying this announcement is
available
at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8746b2f-e840-4d4c-a066-c88332388b2a
"When the COVID-19 crisis began, even before we had our first
confirmed cases, I said that our state was home to some of the top
health research facilities in the world, and I hoped that we might
be a part of developing treatments and perhaps even a vaccine for
this deadly virus," said Governor Hogan. "Novavax took that
challenge and immediately hit the ground running. The State of
Maryland is proud to support the efforts of Novavax and our entire
hub of life sciences companies, which is at the forefront in the
fight against COVID-19."
Dr. Michelle McMurry-Heath spoke about the unprecedented
response by the biotechnology industry to fight COVID-19. “Novavax
is a shining example of that response, that galvanized intellectual
capacity, and the ability to put the power of science to healing
the world,” she said. “We at the Biotechnology Innovation
Organization couldn’t be prouder of how our companies, our
scientists, our entrepreneurs, have really mobilized to change the
world.”
“We are about to enter three different phase 3 trials, including
a trial that is starting imminently in the UK in 10,000 people, a
trial that is starting in the U.S. in a few weeks that will be
30,000 people and a third phase 3 trial in India. We have a global
presence. This is a global disease. I don’t think it’s sufficient
that we have a vaccine that is just used for the United States. To
protect the United States, you need to protect the world. It is a
global economy. And that’s what we’re doing,” Erck said. “We feel a
tremendous responsibility in our role at the forefront of vaccine
development and in our mission to deliver a safe and effective
vaccine as rapidly as possible to help combat
the COVID-19 pandemic. As a science-based organization dedicated to
improving health, it has been gratifying to see
many like-minded stakeholders in our region come together
to that end.”
The remarks were made on-site at Novavax in Gaithersburg,
Maryland. Full video of the remarks is available here.
Media contacts:
BIOTheresa Bradytbrady@bio.org
NovavaxInvestorsSilvia Taylor and Erika
Trahanir@novavax.com240-268-2022MediaBrandzone/KOGS
CommunicationEdna Kaplankaplan@kogspr.com617-974-8659
About BIO
BIO is the world's largest trade association representing
biotechnology companies, academic institutions, state biotechnology
centers and related organizations across the United States and in
more than 30 other nations. BIO members are involved in the
research and development of innovative healthcare, agricultural,
industrial and environmental biotechnology products. BIO also
produces the BIO International Convention, the world’s largest
gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the
world.
For more information visit: https://www.bio.org/ Follow us on
Twitter @IAmBiotechFind us on LinkedIn
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology
company that promotes improved health globally through the
discovery, development, and commercialization of innovative
vaccines to prevent serious infectious
diseases. Novavax is undergoing clinical trials for
NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus
that causes COVID-19. NanoFlu™, its quadrivalent influenza
nanoparticle vaccine, met all primary objectives in its pivotal
Phase 3 clinical trial in older adults. Both vaccine candidates
incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant
in order to enhance the immune response and stimulate high levels
of neutralizing antibodies. Novavax is a leading
innovator of recombinant vaccines; its proprietary recombinant
technology platform combines the power and speed of genetic
engineering to efficiently produce highly immunogenic nanoparticles
in order to address urgent global health needs.
For more information, visit www.novavax.com and connect with us
on Twitter and LinkedIn.
About NVX-CoV2373
NVXCoV2373 is a vaccine candidate engineered from the genetic
sequence of SARSCoV2, the virus that causes COVID-19 disease.
NVXCoV2373 was created using Novavax’ recombinant nanoparticle
technology to generate antigen derived from the coronavirus spike
(S) protein and contains Novavax’ patented saponin-based Matrix-M™
adjuvant to enhance the immune response and stimulate high levels
of neutralizing antibodies. NVX-CoV2373 contains purified protein
antigens and cannot replicate, nor can it cause COVID-19. In
preclinical trials, NVXCoV2373 demonstrated indication of
antibodies that block binding of spike protein to receptors
targeted by the virus, a critical aspect for effective vaccine
protection. In its the Phase 1 portion of its Phase 1/2 clinical
trial, NVXCoV2373 was generally well-tolerated and elicited robust
antibody responses numerically superior to that seen in human
convalescent sera. NVX-CoV2373 is also being evaluated in two
ongoing Phase 2 studies, which began in August; a Phase 2b trial in
South Africa, and a Phase 1/2 continuation in the U.S. and
Australia. Novavax has secured $2 billion in funding
for its global coronavirus vaccine program, including up
to $388 million in funding from the Coalition for
Epidemic Preparedness Innovations (CEPI).
About Matrix-M™
Novavax’ patented saponin-based Matrix-M™ adjuvant has
demonstrated a potent and well-tolerated effect by stimulating the
entry of antigen-presenting cells into the injection site and
enhancing antigen presentation in local lymph nodes, boosting
immune response.
Novavax Forward-Looking Statements
Statements herein relating to the future
of Novavax and the ongoing development of its vaccine and
adjuvant products are forward-looking
statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include those identified under the heading “Risk
Factors” in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2019, and Quarterly Report on Form 8-K for
the period ended June 30, 2020, as filed with
the Securities and Exchange Commission (SEC). We caution
investors not to place considerable reliance on forward-looking
statements contained in this press release. You are encouraged to
read our filings with the SEC, available at sec.gov, for
a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this document, and we undertake no obligation to update
or revise any of the statements. Our business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024